Compile Data Set for Download or QSAR
maximum 50k data
Found 358 with Last Name = 'honigberg' and Initial = 'l'
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1773(US10280174, Comparative Compound 1 | US8476284, 4 ...)
Affinity DataKi:  14nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1773(US10280174, Comparative Compound 1 | US8476284, 4 ...)
Affinity DataKi:  97nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-4(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.100nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-4(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.100nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.200nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.200nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191606(US9181263, 23 | US9278100, 23)
Affinity DataIC50:  0.320nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191606(US9181263, 23 | US9278100, 23)
Affinity DataIC50:  0.320nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14)
Affinity DataIC50:  0.390nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14)
Affinity DataIC50:  0.390nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Fgr(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.400nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Fgr(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.400nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1774(US10894048, Ref. Ex Comp. 1 | US8476284, 13)
Affinity DataIC50: <0.5nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1773(US10280174, Comparative Compound 1 | US8476284, 4 ...)
Affinity DataIC50: <0.5nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1773(US10280174, Comparative Compound 1 | US8476284, 4 ...)
Affinity DataIC50: <0.5nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97673(US8476284, 41 | US8497277, 6)
Affinity DataIC50:  0.520nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM181017(US9133201, 6)
Affinity DataIC50:  0.520nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97673(US8476284, 41 | US8497277, 6)
Affinity DataIC50:  0.520nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.580nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97677(US8476284, 7 | US8497277, 7 | US9133201, 7)
Affinity DataIC50:  0.580nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.580nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97677(US8476284, 7 | US8497277, 7 | US9133201, 7)
Affinity DataIC50:  0.580nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97678(US8476284, 9 | US8497277, 10 | US8497277, 9 | US91...)
Affinity DataIC50:  0.580nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97677(US8476284, 7 | US8497277, 7 | US9133201, 7)
Affinity DataIC50:  0.580nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13)
Affinity DataIC50:  0.670nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13)
Affinity DataIC50:  0.670nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1773(US10280174, Comparative Compound 1 | US8476284, 4 ...)
Affinity DataIC50:  0.720nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97674(US8476284, 42 | US8497277, 8 | US9133201, 8)
Affinity DataIC50:  0.720nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1773(US10280174, Comparative Compound 1 | US8476284, 4 ...)
Affinity DataIC50:  0.720nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97674(US8476284, 42 | US8497277, 8 | US9133201, 8)
Affinity DataIC50:  0.720nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97674(US8476284, 42 | US8497277, 8 | US9133201, 8)
Affinity DataIC50:  0.720nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM1773(US10280174, Comparative Compound 1 | US8476284, 4 ...)
Affinity DataIC50:  0.720nMpH: 7.4Assay Description:Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM220129(US9278100, 18)
Affinity DataIC50:  0.760nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191622(US9181263, 18)
Affinity DataIC50:  0.760nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytoplasmic tyrosine-protein kinase BMX(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Yes(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Yes(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytoplasmic tyrosine-protein kinase BMX(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10)
Affinity DataIC50:  0.880nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10)
Affinity DataIC50:  0.880nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 358 total ) | Next | Last >>
Jump to: